AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17211699 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic 2000 (once daily dose)
Number of subjects: 30
Study 17211699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15851339 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation at anterior coronary vein
Number of subjects: 24
Study 15851339 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation at lateral coronary vein
Number of subjects: 24
Study 15851339 — intervention group
Group type: COMPARATOR
Intervention: Overall stimulation at different sites within a coronary vein
Number of subjects: 24
Study 11999569 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 48
Study 11999569 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 48
Study 11999569 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (radiotherapy followed by chemotherapy)
Number of subjects: 48
Study 9802715 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 25% dental gel applied subgingivally on days 0 and 7
Number of subjects: 46
Study 9802715 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing carried out on days 0 and 7
Number of subjects: 46
Study 8178002 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O2 exposure (prior O2 exposure)
Number of subjects: 0
Study 8178002 — intervention group
Group type: COMPARATOR
Intervention: Ambient air (without prior O2 exposure)
Number of subjects: 0
Study 3722633 — intervention group
Group type: COMPARATOR
Intervention: Nasal challenge with saline
Number of subjects: 11
Study 3722633 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal challenge with Bermuda grass-pollen allergen
Number of subjects: 11
Study 3722633 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal challenge with histamine
Number of subjects: 11
Study 29774884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided radial arterial cannulation
Number of subjects: 120
Study 29774884 — intervention group
Group type: COMPARATOR
Intervention: Traditional blind puncture method
Number of subjects: 120
Study 27752485 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-integrated cognitive behavior therapy
Number of subjects: 80
Study 27752485 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care services
Number of subjects: 80
Study 24993098 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term continuous positive airway pressure (CPAP), n=22, duration 6-8 weeks.
Number of subjects: 45
Study 24993098 — intervention group
Group type: COMPARATOR
Intervention: No CPAP, n=23.
Number of subjects: 45
Study 22727611 — intervention group
Group type: COMPARATOR
Intervention: Warfarin 25 mg alone
Number of subjects: 15
Study 22727611 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin 25 mg coadministered with fimasartan 240 mg
Number of subjects: 15
Study 20942292 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina massage therapy
Number of subjects: 937
Study 20942292 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 937
Study 20942292 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection
Number of subjects: 937
Study 20942292 — intervention group
Group type: COMPARATOR
Intervention: Tuina
Number of subjects: 937
Study 20942292 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina massage
Number of subjects: 937
Study 17069892 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable finger flexion monitor
Number of subjects: 30
Study 16337870 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease subjects
Number of subjects: 3
Study 16337870 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly subjects
Number of subjects: 3
Study 16337870 — intervention group
Group type: COMPARATOR
Intervention: Young adult subjects
Number of subjects: 3
Study 11788225 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 24322
Study 11788225 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (diuretics or beta-blockers)
Number of subjects: 24322
Study 11788225 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 24322
Study 10209370 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange-flavoured glucose (group I)
Number of subjects: 45
Study 10209370 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk (group II)
Number of subjects: 45
Study 10209370 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk (group III)
Number of subjects: 45
Study 10209370 — intervention group
Group type: COMPARATOR
Intervention: Midnight fast (group IV)
Number of subjects: 45
Study 7726351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular injection of 20 ml of 1% lidocaine
Number of subjects: 30
Study 7726351 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injections of morphine sulfate and midazolam
Number of subjects: 30
Study 2292351 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum phosphate
Number of subjects: 91
Study 2292351 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 91
Study 7211734 — intervention group
Group type: EXPERIMENTAL
Intervention: Skim milk
Number of subjects: 0
Study 7211734 — intervention group
Group type: COMPARATOR
Intervention: Yoghurt
Number of subjects: 0
Study 7211734 — intervention group
Group type: COMPARATOR
Intervention: Full cream milk
Number of subjects: 0
Study 7211734 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (skim milk, yoghurt, full cream milk)
Number of subjects: 0
Study 31983312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP goal (<120 mm Hg)
Number of subjects: 2270
Study 31983312 — intervention group
Group type: COMPARATOR
Intervention: Standard BP goal (<140 mm Hg)
Number of subjects: 2270
Study 31983312 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BP goals
Number of subjects: 2270
Study 30685701 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose buprenorphine
Number of subjects: 31
Study 30685701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 28524806 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise intervention
Number of subjects: 214
Study 28524806 — intervention group
Group type: COMPARATOR
Intervention: Health education intervention
Number of subjects: 214
Study 25828601 — intervention group
Group type: EXPERIMENTAL
Intervention: His-bundle pacing (HBP)
Number of subjects: 29
Study 25828601 — intervention group
Group type: COMPARATOR
Intervention: Biventricular pacing (BiVP)
Number of subjects: 29
Study 24067797 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA/DHA-rich liquid diet
Number of subjects: 30
Study 24067797 — intervention group
Group type: COMPARATOR
Intervention: Liquid diet lacking EPA/DHA
Number of subjects: 30
Study 21422081 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 101
Study 21422081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 19280831 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR + CAF
Number of subjects: 7
Study 19280831 — intervention group
Group type: COMPARATOR
Intervention: CAF alone
Number of subjects: 7
Study 17267744 — intervention group
Group type: EXPERIMENTAL
Intervention: FIR therapy for 1 year
Number of subjects: 145
Study 16221350 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (NNS)
Number of subjects: 38
Study 16221350 — intervention group
Group type: COMPARATOR
Intervention: N-NNS (control)
Number of subjects: 38
Study 11254512 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenopausal women
Number of subjects: 12219
Study 11254512 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women with hormone replacement therapy (HRT)
Number of subjects: 12219
Study 11254512 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women without HRT
Number of subjects: 12219
Study 11254512 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 12219
Study 11254512 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of sleep apnea prevalence
Number of subjects: 12219
Study 11254512 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal women without HRT compared to premenopausal women with HRT
Number of subjects: 12219
Study 11254512 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal women without HRT compared to men
Number of subjects: 12219
Study 9635849 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 20
Study 9635849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 20
Study 7596206 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Inpatient Management Model (clinical information system)
Number of subjects: 2000
Study 7596206 — intervention group
Group type: COMPARATOR
Intervention: Control service (historic norms)
Number of subjects: 2000
Study 7596206 — intervention group
Group type: COMPARATOR
Intervention: Control service
Number of subjects: 2000
Study 7596206 — intervention group
Group type: EXPERIMENTAL
Intervention: Other internal medicine services
Number of subjects: 2000
Study 2551204 — intervention group
Group type: COMPARATOR
Intervention: BID regimen (twice a day)
Number of subjects: 53
Study 2551204 — intervention group
Group type: EXPERIMENTAL
Intervention: QID regimen (four times a day)
Number of subjects: 53
Study 776326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-clean air theatre
Number of subjects: 0
Study 776326 — intervention group
Group type: COMPARATOR
Intervention: Conventional theatre
Number of subjects: 0
Study 30418579 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 LCPUFA (2.4 g daily)
Number of subjects: 699
Study 30418579 — intervention group
Group type: COMPARATOR
Intervention: Control (olive oil)
Number of subjects: 699
Study 28614905 — intervention group
Group type: EXPERIMENTAL
Intervention: ROAD (rituximab, oxaliplatin, cytarabine, dexamethasone)
Number of subjects: 45
Study 26100924 — intervention group
Group type: EXPERIMENTAL
Intervention: 90μg HPV vaccine
Number of subjects: 1600
Study 26100924 — intervention group
Group type: EXPERIMENTAL
Intervention: 60μg HPV vaccine
Number of subjects: 1600
Study 26100924 — intervention group
Group type: EXPERIMENTAL
Intervention: 30μg HPV vaccine
Number of subjects: 1600
Study 26100924 — intervention group
Group type: COMPARATOR
Intervention: Control hepatitis B vaccine
Number of subjects: 1600
Study 22906966 — intervention group
Group type: EXPERIMENTAL
Intervention: Autopulse™ ZOLL mechanical CPR device with 'pit-crew' protocol
Number of subjects: 248
Study 20337634 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg b.i.d. on Day 5 of a 7-day regimen
Number of subjects: 0
Study 20337634 — intervention group
Group type: COMPARATOR
Intervention: Laropiprant 40 mg alone
Number of subjects: 0
Study 19298202 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-diet
Number of subjects: 35
Study 19298202 — intervention group
Group type: EXPERIMENTAL
Intervention: L-diet
Number of subjects: 35
Study 19298202 — intervention group
Group type: COMPARATOR
Intervention: C-diet
Number of subjects: 35
Study 19298202 — intervention group
Group type: EXPERIMENTAL
Intervention: FF-diet
Number of subjects: 35
Study 17643983 — intervention group
Group type: EXPERIMENTAL
Intervention: No anxiety whilst awaiting the PSA test results
Number of subjects: 1781
Study 17643983 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of anxiety whilst awaiting the PSA test results
Number of subjects: 1781
Study 17643983 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety influenced by previously elevated PSA tests
Number of subjects: 1781
Study 17643983 — intervention group
Group type: EXPERIMENTAL
Intervention: No anxiety associated with biopsy
Number of subjects: 1781
Study 17643983 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of anxiety associated with biopsy
Number of subjects: 1781
Study 17643983 — intervention group
Group type: EXPERIMENTAL
Intervention: Levels of anxiety with subsequent rounds of examinations
Number of subjects: 1781
Study 17643983 — intervention group
Group type: EXPERIMENTAL
Intervention: Levels of anxiety with increasing age
Number of subjects: 1781
Study 15571110 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (FI) school
Number of subjects: 3
Study 15571110 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-intervention (SI) school
Number of subjects: 3
Study 15571110 — intervention group
Group type: COMPARATOR
Intervention: Control (C) school
Number of subjects: 3
Study 15571110 — intervention group
Group type: EXPERIMENTAL
Intervention: Before summer vacation measurements
Number of subjects: 3
Study 15571110 — intervention group
Group type: EXPERIMENTAL
Intervention: After summer vacation measurements
Number of subjects: 3
Study 11276502 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborns of smoking mothers
Number of subjects: 0
Study 11276502 — intervention group
Group type: COMPARATOR
Intervention: Newborns of non-smoking mothers
Number of subjects: 0
Study 11229106 — intervention group
Group type: EXPERIMENTAL
Intervention: prazosin GITS 2.5 mg OD
Number of subjects: 24
Study 11229106 — intervention group
Group type: COMPARATOR
Intervention: atenolol 50 mg OD
Number of subjects: 24
Study 11229106 — intervention group
Group type: COMPARATOR
Intervention: nifedipine SR 20 mg BD
Number of subjects: 24
Study 11229106 — intervention group
Group type: COMPARATOR
Intervention: enalapril 5 mg OD
Number of subjects: 24
Study 7887113 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 32
Study 7887113 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 32
Study 7887113 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium (2 x ED90) and Vecuronium (1/2 x ED90)
Number of subjects: 32
Study 7887113 — intervention group
Group type: COMPARATOR
Intervention: EMG TOF ratio
Number of subjects: 32
Study 7887113 — intervention group
Group type: EXPERIMENTAL
Intervention: First dorsal interosseous EMG amplitude and area
Number of subjects: 32
Study 3497450 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (1200 mg)
Number of subjects: 53
Study 3497450 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole (480/2400 mg)
Number of subjects: 53
Study 29104121 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesatolimod (1-, 2-, or 4-mg doses) administered once weekly for 4, 8, or 12 weeks
Number of subjects: 162
Study 29104121 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) administered once weekly for 4, 8, or 12 weeks
Number of subjects: 162
Study 28342578 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 441mg
Number of subjects: 309
Study 28342578 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 882mg
Number of subjects: 309
Study 28342578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 26378397 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited care pathway (24-h admission)
Number of subjects: 40
Study 26378397 — intervention group
Group type: COMPARATOR
Intervention: Control (72-h admission)
Number of subjects: 40
Study 23383976 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) program (8 weeks)
Number of subjects: 100
Study 21667452 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-hour social skills training (TEAM)
Number of subjects: 40
Study 21667452 — intervention group
Group type: COMPARATOR
Intervention: Untreated waiting control group
Number of subjects: 40
Study 19807952 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to comprehensive electronic medical records (EMRs)
Number of subjects: 61
Study 19807952 — intervention group
Group type: COMPARATOR
Intervention: No access to comprehensive EMRs
Number of subjects: 61
Study 16998266 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (angiotensin II type 1 receptor blocker)
Number of subjects: 400
Study 16998266 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (dihydropiridine calcium antagonist)
Number of subjects: 400
Study 14696522 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoComb dressing (collagen mesh covered by fibrin glue) applied in 29 cases
Number of subjects: 54
Study 14696522 — intervention group
Group type: COMPARATOR
Intervention: Gas compresses (control group) used in 25 patients
Number of subjects: 54
Study 11049913 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 2.5 mg/kg (Group 1)
Number of subjects: 50
Study 11049913 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 1.25 mg/kg + lysine acetyl salicylate 12.5 mg/kg (Group 2)
Number of subjects: 50
Study 9284852 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (reversed microdialysis)
Number of subjects: 24
Study 9284852 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (reversed microdialysis)
Number of subjects: 24
Study 9284852 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound 48/80 (reversed microdialysis)
Number of subjects: 24
Study 1329673 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (50 mg injections three times a week for six weeks)
Number of subjects: 16
Study 1329673 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (continued for an additional six weeks in group A)
Number of subjects: 16
Study 1329673 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group B)
Number of subjects: 16
Study 1329673 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin treatment
Number of subjects: 16
Study 3919557 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil once daily
Number of subjects: 33
Study 3919557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 31605792 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 106
Study 31605792 — intervention group
Group type: COMPARATOR
Intervention: Comparator (EGFR tyrosine kinase inhibitors)
Number of subjects: 106
Study 31058358 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher upper-limbs absolute strength
Number of subjects: 79
Study 31058358 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher lower-limbs relative-to-weight strength
Number of subjects: 79
Study 31058358 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher speed-agility
Number of subjects: 79
Study 31058358 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cardiorespiratory fitness levels
Number of subjects: 79
Study 31058358 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous physical activity
Number of subjects: 79
Study 31058358 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time and other PA intensities
Number of subjects: 79
Study 30442122 — intervention group
Group type: COMPARATOR
Intervention: Current practice of BP lowering therapy
Number of subjects: 62194
Study 30442122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate risk threshold for BP lowering therapy
Number of subjects: 62194
Study 30442122 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk threshold for BP lowering therapy
Number of subjects: 62194
Study 26369526 — intervention group
Group type: COMPARATOR
Intervention: 40 mg basiliximab with cyclosporine (control)
Number of subjects: 16
Study 26369526 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg basiliximab with cyclosporine
Number of subjects: 16
Study 26369526 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg basiliximab with everolimus (CNI-free)
Number of subjects: 16
Study 24481719 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 123
Study 24481719 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed
Number of subjects: 123
Study 22682340 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive metric parameters (age, weight, height, body surface area, body mass index)
Number of subjects: 46
Study 22682340 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of red cell volume after 4 weeks
Number of subjects: 46
Study 22682340 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of plasma volume
Number of subjects: 46
Study 19183087 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management
Number of subjects: 53
Study 19183087 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amitriptyline (10-20 mg/day)
Number of subjects: 53
Study 19183087 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical triamcinolone plus oral amitriptyline (10-20 mg/day)
Number of subjects: 53
Study 19183087 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 53
Study 17937333 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (PSA analysis and sextant prostate biopsy)
Number of subjects: 4278
Study 17937333 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no PSA analysis or biopsy)
Number of subjects: 4278
Study 17937333 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm
Number of subjects: 4278
Study 17937333 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 4278
Study 15823767 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix 75/25 plus metformin
Number of subjects: 105
Study 15823767 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine plus metformin
Number of subjects: 105
Study 11223660 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical cardioversion (CV) of atrial fibrillation after at least 3 weeks of effective anticoagulation
Number of subjects: 29
Study 11223660 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical cardioversion (CV) of atrial fibrillation
Number of subjects: 29
Study 9844163 — intervention group
Group type: EXPERIMENTAL
Intervention: High-voltage pulsed current electrical stimulation
Number of subjects: 132
Study 7818782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fetal cardiac sampling in the left or right uterine horn
Number of subjects: 0
Study 7818782 — intervention group
Group type: COMPARATOR
Intervention: Unsampled uterine horns
Number of subjects: 0
Study 7818782 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal hematologic parameters
Number of subjects: 0
Study 2732023 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol maleate 0.5%
Number of subjects: 19
Study 2732023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 1056055 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic training (fast speed)
Number of subjects: 48
Study 1056055 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic training (slow speed)
Number of subjects: 48